Viatris Inc.VTRS

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · viatris.com

Viatris Inc. is a global healthcare company that provides prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients. The company operates through segments including Developed Markets, Greater China, JANZ, and Emerging Markets, serving therapeutic areas such as cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare. Headquartered in Canonsburg, Pennsylvania, Viatris serves patients in more than 165 countries and territories.

Key ratios

Operating cash flow growth

12.9%TTM

2025 0.6%2024 -20.6%2023 -3.3%

EPS growth

-97.3%2023

FCF / Sales

13.3%TTM

2025 13.5%2024 13.4%2023 16.4%

Net margin

-2.8%TTM

2025 -24.6%2024 -4.3%2023 0.4%

ROA

2.7%TTM

2025 2.0%2024 2.2%2023 2.6%

ROE

-2.8%TTM

2025 -21.1%2024 -3.2%2023 0.3%

Revenue growth

4.4%TTM

2025 -3.0%2024 -4.5%2023 -5.1%

Recent news

Viatris Completes €650 Million 4.250% Senior Notes Due 2033 to Refinance 2026 Debt 2026-06-18 · TradingView U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain 2026-05-18 · Viatris Newsroom

Track VTRS in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer